Macrolides in the treatment of community-acquired infections of lower respiratory tract
https://doi.org/10.21518/2079-701X-2013-5-26-30
Abstract
Infections of the lower respiratory tract are a serious challenge for modern healthcare. Macrolides occupy a special place in the list of antibiotics recommended for the treatment of such conditions, which is not only due to their high safety and efficiency associated with their potent activity against major pathogens; macrolides are also characterized by unique non-antibiotic properties. The review highlights specific use of macrolides today for pneumonia and infectious exacerbation of chronic obstructive pulmonary disease/chronic bronchitis in view of the immunomodulatory and anti-inflammatory properties of the drugs.
Keywords
небальничные инфекции дыхательных путей,
пневмония,
инфекционное обострение хронической обструктивной болезни легких/хронического бронхита,
антимикробные препараты,
community-acquired respiratory tract infections,
pneumonia,
infectious exacerbation of chronic obstructive pulmonary disease/chronic bronchitis,
antimicrobials
About the Authors
A. V. Golub
Research Institute of Antimicrobial Chemotherapy of the Smolensk State Medical Academy, Russia's Ministry of Health
Russian Federation
Russian Federation
R. S. Kozlov
Research Institute of Antimicrobial Chemotherapy of the Smolensk State Medical Academy, Russia's Ministry of Health
Russian Federation
Russian Federation
References
1. Синопальников А.И., Козлов Р.С. Внебольничные инфекции дыхательных путей: руководство для врачей. М.: Премьер МТ Наш Город, 2007.
2. Martinez F.J., Curtis J.L., Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease // Int. J. Chron. Obstruct. Pulmon. Dis. 2008. №3. P. 331-50.
3. Козлов Р.С, Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность S. pneumoniae в России в 1999-2005 гг.: результаты многоцентровых проспективный: исследований ПеГАС I и ПеГАС II // Клин. микробиол. и антимикроб. химиотер. 2006. №8. C. 33-47.
4. Научный отчет о результатах исследования эпидемиологии антимикробной резистентности клинических штаммов S. pneumoniae в России (по данным многоцентрового исследования ПеГАС III). Смоленск, 2010.
5. Страчунский Л.С., Тарасов А.А., Крюков А.И. и др. Возбудители острого бактериального синусита // Клин. микробиол. и антимикроб. химиотер. 2005. №7. С. 337-49.
6. Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Внебольничная пневмония у взрослый: практические рекомендации по диагностике, лечению и профилактике // Клин. микробиол. и антимикроб. химиотер. 2006. №8. С. 54-86.
7. Roche N., Huchon G. Epidemiology of chronic obstructive pulmonary disease // Rev. Prat. 2004. №54. P 1408-1413.
8. Mapel D., Chen J.C., George D. et al. The cost of chronic obstructive pulmonary disease and its effects on managed care // Manag. Care Interface. 2004. №17. P 61-66.
9. Anzueto A., Niederman M.S., Tillotson G.D. et al. Etiology, susceptibility and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg BID vs clarithromycin 500 mg BID // Clin. Ther. 1998. №20. P. 885-900.
10. Chodosh S., Schreurs J.M., Siami G. et al. Efficacy of oral ciprofloxacin vs clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis // Clin. Infect. Dis. 1998. №27. P. 730-738.
11. Read R.C., Kuss A., Berrisoul F. et al. The efficacy and safety of a new ciprofloxacin suspension compared with co-amoxiclav tablets in the treatment of acute exacerbation of chronic bronchitis // Respir. Med. 1999. №93. P. 252-261.
12. Schonwald S., Barsic B., Klinar I. et al. Three-day azitromycin compared with ten-day roxithromycin treatment of atypical pneumonia // Scand J. Infect. Dis. 1994. №26. P. 706-710.
13. Веселов А.В., Козлов Р.С. Азитромицин: современные аспекты клинического применения // Клин. микробиол. и антимикроб. химиотер. 2006. №8. С. 18-32.
14. Brysker A., Bergogne-Berezin E. Macrolides. Antibacterial and antifungal agents. Brysker A. ed. ASM-Press Washington, DC. 2005.
15. Amsden G.W. Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? // J. Antimicrob. Chemother. 2005. №55. P 10-21.
16. Culic O., Erakovic V., Cepelak I. et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects // Eur. J. Pharmacol. 2002. №450. P. 277-289.
17. Koch C.C., Esteban D.J., Chin A.C. et al. Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae // J. Antimicrob. Chemother. 2000. №46. P. 19-26.
18. Parnham M.J., Culic O., Erakovic V. et al. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment // Eur. J. Pharmacol. 2005. №517. P. 132-143.
19. Lonks J.R., Garau J., Gomez L. et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumonia // Clin. Infect. Dis. 2002. №35. P. 556-564.
20. Gleason PP., Meehan TP, Fine J.M. et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia // Arch. Intern. Med. 1999. №159. P 2562-2572.
21. Brown R.B., Iannini P, Gross P. et al. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database // Chest. 2003. №123. P. 1503-1511.
Review
For citations:
Golub AV, Kozlov RS. Macrolides in the treatment of community-acquired infections of lower respiratory tract. Meditsinskiy sovet = Medical Council. 2013;(5):26-30. (In Russ.) https://doi.org/10.21518/2079-701X-2013-5-26-30
Views:
400
Email this article 